share_log

Firefly Neuroscience | 10-Q: Q3 2024 Earnings Report

Firefly Neuroscience | 10-Q: Q3 2024 Earnings Report

Firefly Neuroscience | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/15 06:32

Moomoo AI 已提取核心訊息

Firefly Neuroscience reported Q3 2024 financial results with revenue of $33,000, up 43% YoY, and a net loss of $4.3 million compared to $650,000 in Q3 2023. Operating expenses increased significantly to $4.3 million from $670,000 last year, primarily due to merger-related costs and share-based compensation expenses following the completion of its merger with WaveDancer in August 2024.Research and development expenses rose 124% YoY to $878,000, while selling and marketing expenses increased to $431,000 from $95,000. General and administrative expenses grew substantially to $3 million, driven by management compensation, legal fees, and public company costs. The company ended the quarter with $1.2 million in cash, down from $2.1 million at year-end 2023.Looking ahead, Firefly plans to launch commercial operations for its FDA-cleared Brain Network Analytics (BNA) Platform in the first half of 2025. The company aims to generate revenue through neurologist adoption in the United States and collaborations with pharmaceutical companies, though management noted substantial doubt about the company's ability to continue as a going concern without additional funding.
Firefly Neuroscience reported Q3 2024 financial results with revenue of $33,000, up 43% YoY, and a net loss of $4.3 million compared to $650,000 in Q3 2023. Operating expenses increased significantly to $4.3 million from $670,000 last year, primarily due to merger-related costs and share-based compensation expenses following the completion of its merger with WaveDancer in August 2024.Research and development expenses rose 124% YoY to $878,000, while selling and marketing expenses increased to $431,000 from $95,000. General and administrative expenses grew substantially to $3 million, driven by management compensation, legal fees, and public company costs. The company ended the quarter with $1.2 million in cash, down from $2.1 million at year-end 2023.Looking ahead, Firefly plans to launch commercial operations for its FDA-cleared Brain Network Analytics (BNA) Platform in the first half of 2025. The company aims to generate revenue through neurologist adoption in the United States and collaborations with pharmaceutical companies, though management noted substantial doubt about the company's ability to continue as a going concern without additional funding.
Firefly Neural科學在2024年第三季度報告了財務結果，營業收入爲33,000美元，同比增長43%，淨虧損爲430萬美元，較2023年第三季度的650,000美元有所減少。營業費用顯著增加，從去年的670,000美元升至430萬美元，主要是由於與合併相關的成本和基於股票的補償費用，這些費用是在2024年8月與WaveDancer完成合並後產生的。研發費用同比增長124%，達到878,000美元，而銷售和市場費用則從95,000美元增加到431,000美元。一般和管理費用顯著增長至300萬美元，主要受到管理補償、法律費用和上市公司成本的推動。公司在本季度結束時現金爲120萬美元，較2...展開全部
Firefly Neural科學在2024年第三季度報告了財務結果，營業收入爲33,000美元，同比增長43%，淨虧損爲430萬美元，較2023年第三季度的650,000美元有所減少。營業費用顯著增加，從去年的670,000美元升至430萬美元，主要是由於與合併相關的成本和基於股票的補償費用，這些費用是在2024年8月與WaveDancer完成合並後產生的。研發費用同比增長124%，達到878,000美元，而銷售和市場費用則從95,000美元增加到431,000美元。一般和管理費用顯著增長至300萬美元，主要受到管理補償、法律費用和上市公司成本的推動。公司在本季度結束時現金爲120萬美元，較2023年年底的210萬美元減少。展望未來，Firefly計劃在2025年上半年推出其獲得FDA批准的腦網絡分析（BNA）平台的商業運營。該公司旨在通過在美國的神經科醫生採用和與藥品公司的合作實現營業收入，儘管管理層指出，如果沒有額外資金，公司在持續經營方面存在重大疑慮。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Jet.AI
    JTAI
    -- 6.030
    文遠知行
    WRD
    -- 31.500
    Blaize Holdings
    BZAI
    -- 5.150
    金山雲
    KC
    -- 20.810
    Procore Technologies
    PCOR
    -- 87.500
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。